Evidence map›Paper›PMID 30913504›Full record

ArticleInternational journal of pediatric otorhinolaryngology2019

Prevention of cisplatin-induced hearing loss by extended release fluticasone propionate intracochlear implants.

Erik Pierstorff, Wan-Wan Yang, Yen-Jung Angel Chen, Shirley Cheung, Federico Kalinec, William H Slattery

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pediatric otorhinolaryngology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Transtympanic Injection of Antioxidant-Eluting Microparticles for Otoprotection From Cisplatin Toxicity in a Mouse Model.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Erik PierstorffO-Ray Pharma, Inc., 2285 E. Foothill Blvd, Pasadena, CA, 91107, USA. Electronic address: epierstorff@oraypharma.com.
Wan-Wan YangO-Ray Pharma, Inc., 2285 E. Foothill Blvd, Pasadena, CA, 91107, USA.
Yen-Jung Angel ChenDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA.
Shirley CheungO-Ray Pharma, Inc., 2285 E. Foothill Blvd, Pasadena, CA, 91107, USA.
Federico KalinecDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA.
William H SlatteryO-Ray Pharma, Inc., 2285 E. Foothill Blvd, Pasadena, CA, 91107, USA.
O-Ray Pharma (United States) · USUniversity of California, Los Angeles · US

Funding

Sustained Release Inner Ear Delivery of CorticosteroidR44DC008477 · NIDCD · O-RAY PHARMA, INC. · PI PIERSTORFF, ERIK, SLATTERY, WILLIAM H · 2010 to 2015
$2.4M
NIDCD NIH HHS R44 DC008477
6 · The paper itself

Abstract

objectiveCisplatin is a chemotherapeutic drug known to induce hearing loss. Although corticosteroids may help to mitigate the ototoxic side effects of cisplatin, there are complications associated with their systemic and prolonged use. The goal of this study is to test the efficacy of extended-release fluticasone propionate intracochlear implant particles to protect against cisplatin-induced hearing loss.

methodsWe used guinea pigs (n = 9) injected with cisplatin (IP, 12 mg/kg weight). Fluticasone particles were delivered to the cochlear scala tympani through the round window membrane into the right ears of the guinea pigs (left ears being used as a control) two weeks prior to cisplatin administration, and hearing function was evaluated by ABR and DPOAE before implantation, immediately before cisplatin administration, and 2 weeks after the challenge with cisplatin. Data was statistically evaluated using paired t-test analysis.

resultsNo significant differences were observed in ABR threshold between control and implanted ears on day 14 (23.9 ± 2.3 dB vs. 25.6 ± 1.3 dB, P = 0.524), whereas the significant cisplatin-induced hearing loss in control animals (23.9 ± 2.3 dB at day 14 vs. 40.7 ± 2.5 dB at day 28, P ≤ 0.0001) was prevented in implanted animals (25.6 ± 1.3 dB at day 14 vs. 25.0 ± 3.1 at day 28, P ≥ 0.85). A similar, though not statistically significant, trend was observed in DPOAE responses in untreated ears (7.9 ± 5.8 dB at day14 vs. -0.5 ± 5.3 dB at day 28, P = 0.654) as compared to treatment (11.1 ± 3.4 dB at day 14 vs. 13.6 ± 4.8 dB at day 28, P = 0.733).

conclusionThese results suggest that fluticasone intracochlear implants are safe and able to provide effective otoprotection against cisplatin-induced hearing loss in the guinea pig model.

Indexed as

AnimalsAnti-Inflammatory AgentsAntineoplastic AgentsAuditory ThresholdCisplatinDelayed-Action PreparationsDrug ImplantsEvoked Potentials, Auditory, Brain StemFluticasoneGuinea PigsHearingHearing LossOtoacoustic Emissions, SpontaneousScala TympaniAnti-Inflammatory AgentsAntineoplastic AgentsCisplatinDelayed-Action PreparationsDrug ImplantsFluticasoneCisplatinCochleaCorticosteroidsImplantationOtotoxicity

Identifiers

PMID30913504
PMCPMC6502669
OpenAlexW2923454124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.